NCT06583070View on ClinicalTrials.gov

SABR Combined with Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Radiation TherapyMetastatic Renal CancerRecurrent Renal Cell Cancer
Interventions
RADIATION

Radiation therapy

Administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions in conjunction with targeted and immunotherapy

DRUG

Targeted and immunotherapy

Targeted and immunotherapy

Trial Locations (2)

100034

RECRUITING

Peking University First Hospital, Beijing

100091

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Third Hospital

OTHER

lead

Peking University First Hospital

OTHER